^
    Back
    Association details:
    Biomarker:TROAP overexpression
    Cancer:Hepatocellular Cancer
    Drug:AZ191 (DYRK1B inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Cell Death Dis
    Title:

    TROAP switches DYRK1 activity to drive hepatocellular carcinoma progression

    Published date:
    01/26/2021
    Excerpt:
    Combination of cisplatin with an inhibitor of DYRK1 AZ191 effectively inhibited tumor growth in mouse model for HCC cells with high level of TROAP.
    Secondary therapy:
    cisplatin
    DOI:
    10.1038/s41419-021-03422-3